Champix varenicline regulatory update

EMA's CHMP concluded the slightly increased risk of cardiovascular events reported from a meta-analysis of Champix varenicline from Pfizer does not outweigh the benefits of the smoking cessation drug.

Read the full 297 word article

User Sign In